

Efficacy and reliability of Matrix PRP in erectile dysfunction therapy: Experience of the regenerative medicine center at CHEIKH KHALIFA University Hospital, Morocco

Abstract

Introduction: Platelet-rich plasma is defined as a plasma fraction derived from autologous blood with a platelet concentration above the normal range. It constitutes a reservoir of bioactive proteins, mainly growth factors, which are essential for initiating and accelerating tissue repair and regeneration. Biological stimulation of damaged tissue with platelet concentrates (PRP) involves harnessing the tissue's regenerative potential by recruiting local stem cells.

Methods: This is a retrospective study spread over 12 months (March 2021 to March 2022) involving a sample of 40 patients with erectile dysfunction with an age ranging from 34 to 71 years and an average of 52.5 years. Initial assessment and follow-up of patients was based on the International Index of Erectile Function (IIEF5) with a score of (5-10) indicating severe erectile dysfunction, (11-15) moderate, (16-20) mild, (21-25) no erectile dysfunction.

Results: All in all, a significant improvement in IEF5 was demonstrated in all patients, with the mean IEF5 of all patients rising uniformly after each dose, plateauing at months 3 and 6.

Conclusion The IEF5 of 55% of patients improved after the 1st dose, with 70% of patients showing improvement after the 2nd dose, then stagnating at 80% after the 3rd dose.

Keywords: Platelet-rich plasma, autologous blood, growth factors, regeneration, Erectile dysfunction

Introduction

Erectile dysfunction is defined as the inability to initiate or maintain a satisfying sexual relationship. It is a very common pathology throughout the world, with the main risk factors being metabolic syndrome, diabetes and smoking. Apart from its pure pathophysiological side as much as its organic disease, erectile dysfunction causes a significant psychological burden on the sufferer, which is very poorly tolerated in conservative Eastern societies, as well as dissatisfaction in the partner, threatening the stability of the conjugal relationship on an ongoing basis.

The advent of IPDE5s at the end of the 90s certainly revolutionized the management of ED, but patient dissatisfaction remains fairly common. Not to mention the considerable percentage of side effects, the limits imposed by contraindications, and the fairly high cost of a complete therapeutic regimen that remains inaccessible to a large segment of the population in an emerging country like ours.

Platelet-rich plasma is defined as a plasma fraction derived from autologous blood with a platelet concentration above the normal range. It constitutes a reservoir of bioactive proteins, mainly growth factors, which are essential for initiating and accelerating tissue repair and regeneration. Biological stimulation of damaged tissue with platelet concentrates (PRP) involves harnessing the tissue's regenerative potential by recruiting local stem cells.

In terms of erectile dysfunction, PRP injection seems to be experimentally effective, nevertheless clinical studies remain rare and timid in this direction, we report in this article the experience of the International Center of Regenerative Medicine of the University Hospital CHEIKH KHALIFA of Casablanca, We assume that PRP injection would be beneficial to treat erectile dysfunction and we verify the efficacy and tolerance of this therapy on our patients.

Patients and methods

This is a retrospective study spread over 12 months (March 2021 to March 2022) involving a sample of 40 patients with erectile dysfunction with an age ranging from 34 to 71 years and an average of 52.5 years. Initial assessment and follow-up of patients was based on the International Index of Erectile Function (IIEF5) with a score of (5-10) indicating severe erectile dysfunction, (11-15) moderate, (16-20) mild, (21-25) no erectile dysfunction.

IIEF5 was assessed before each PRP injection and periodically at 3 and 6 months. We opted for a standard 3-injection regimen (one injection every 15 days). No patient in the study was receiving any other treatment for erectile dysfunction.

Preparation of Matrix PRP

To prepare PRP, the patient's blood was collected in a sterile vacuum tube containing 0.5 ml sodium citrate (anticoagulant) and 2 ml non-cross-linked hyaluronic acid (HA) (under the inert separating gel). The tubes were then centrifuged at 3000 rpm for 5 minutes. The plasma and HA layers were then homogenized (the inert gel separating them from the red blood cells and leukocyte ring).

The aim was to recover a maximum number of platelets deposited on the surface of the separating gel, thereby obtaining a platelet-enriched combination of Plasma + HA (with a final concentration slightly higher than its physiological value, and a viability of 70%). 3 cc of Matrix PRP were injected into each corpus cavernosum with a 25G needle.

No anesthesia was applied at the injection site.

During the intracavernosal injection, a tourniquet was applied for 20 minutes to ensure maximum retention of the PRP at the injection site and to optimize its action in contact with the corpora cavernosa, while limiting any wastage and avoiding compression of the dorsal penile artery, as well as the superficial and deep dorsal vein.

Intracavernosal autologous PRP was applied to patients 3 times at 15-day intervals. Injection sites varied from 1 cm in the median region of the penis. Due to the limited number of studies on PRP and erectile dysfunction, there is no clear consensus. In this study, we used this dose and time interval in line with similar studies with PRP.

Results

Patient demographics are shown in Table 1, 3 patients were excluded (out of follow-up), age ranged from 34 to 71 years with an average of 52,5 years.

36 patients (90%) were married, 2 divorced and 2 single. Body mass index averaged 32.2.

18 patients (45%) were known diabetics, 10 patients (25%) were hypertensive, 12 patients (30%) were known dyslipidemics, 6 patients (15%) were glucose intolerant, 4 patients had undergone cystectomy, 2 patients had undergone prostatectomy.

No patient experienced significant pain during the injection, very minimal bleeding was observed in 2 patients, 1 patient presented a local inflammatory reaction 3 cm in diameter which resolved spontaneously after 2 hours, no patient presented urethral discharge of the injection fluid.

All in all, a significant improvement in IEF5 was demonstrated in all patients, with the mean IEF5 of all patients rising uniformly after each dose, plateauing at months 3 and 6.

The IEF5 of 55% of patients improved after the 1st dose, with 70% of patients showing improvement after the 2nd dose, then stagnating at 80% after the 3rd dose.

Table 1 :List of variables and their values

Variable	Value
Average Age	52,5

Familystatus	
Married	36 patients (90%)
Divorced	2 patients (5%)
Single	2patients (5%)
BMI(average)	32,2
Duration of erectiledysfunction	6 ans
HTA	12 patients (30%)
Diabetes	18 patients (45%)
Dyslipidemia	12 patients (30%)
Impaired glucose tolerance	6 patients (15%)
Cystectomy	4 patients (10%)
Prostatectomy	2 patients (5%)




Fig. 1. Bar graph showing improvement in IEF5




Fig .2 : Evolution of IEF5

Discussion

Erectile dysfunction (ED) is the most widely studied sexual dysfunction. It is defined as the persistent or recurrent inability to obtain or maintain an erection permitting satisfactory sexual intercourse.

The prevalence of ED is less than 10% in men under 50, and more than 20% in men over 60. Aging, cardiovascular disease as a whole, diabetes, hypercholesterolemia, smoking, depression and psychiatric illnesses, psychological disorders and unfavorable socioeconomic conditions are all risk factors for ED. Drug-induced ED must be systematically investigated. ED can be psychogenic, organic or mixed: psychogenic and organic.

The pathophysiological mechanisms are diverse, involving alterations in central or peripheral nerve control, penile arterial vascularization, endothelial function, smooth muscle tone and the structure of the corpora cavernosa, and even hormonal involvement. Indeed, ED may be a symptom of an underlying vascular disorder. The probability of developing vasogenic ED is increased by 3.04 times in hypertension, 2.57 times in diabetes and 1.83 times in dyslipidemia. Prospective and cross-sectional studies have found that obesity and metabolic syndrome are associated with increased ED.

The management of erectile dysfunction is as complex as its etiopathogenesis, and highly effective treatment remains a challenge for the clinician given the multitude of pathophysiological parameters involved. IPDE5s are the most widely used therapeutic class, with daily regimens or on-demand injections before intercourse. Intracavernosal injections of prostaglandins are an alternative to IPDE5s, stimulating cyclic AMP and thus promoting muscle fiber relaxation and vasodilation, which are essential for erection.

However, all these treatments face 3 main challenges:

- symptomatic therapies, none of which can cure ED

- average patient satisfaction, especially after long-term use

- High cost

Recently, new therapeutic strategies have been tested for erectile dysfunction and Peyronie's disease, aimed at repairing the penile cellular lesions at the root of the disorder. These new therapies involve injecting autologous biological products into the corpora cavernosa, with the aim of improving erectile function and/or reducing albuginea fibrosis.

Platelet-rich plasma (PRP) is blood plasma enriched with platelets by centrifugation, thus eliminating the majority of leukocytes and erythrocytes. It is a concentrated source of autologous platelets which, once injected, release platelet factors responsible for tissue healing by degranulation. The main platelet factors released are VEGF (Vascular Endothelial Growth Factor), FGF (Fibroblast Growth Factor), IGF (Insulin-like Growth Factor), TGF (Transforming Growth Factor), PDGF-AB (Platelet-Derived Growth Factor). These factors influence cell growth and collagen synthesis, and activate angiogenesis. They therefore represent a set of signals capable of stimulating cell growth and remodeling of damaged tissue, justifying their interest as inducers of healing in poorly vascularized tissue.

PRP was first used for a variety of aesthetic indications, before being extended to pathologies involving muscle, cartilage, tendon or nerve regeneration. Although several clinical studies have shown unquestionable regenerative effects on a wide range of tissues, the lack of standardization of the manufacturing process has led to considerable heterogeneity in product composition, making it impossible to compare results.

"Despite accumulating evidence from molecular and animal studies, limited data suggest the use of PRP in daily clinical practice". [25]

In a double-arm randomized clinical trial, Evangelos Poulos et al. compared a group of 30 mild ED patients receiving a monthly intracavernosal injection of PRP with a similar group receiving placebo and assessed at months one, three and six. The trial showed a significant gain of 3.9 points in IEF5 score and satisfaction in patients treated with PRP. The authors concluded that PRP is a promising therapeutic alternative for the treatment of ED.

"In a multicenter randomized Russian study, patients with erectile dysfunction were divided into 3 groups: (Group 1, 30 patients): three sessions of intracavernosal injections of activated PRP with 10% CaCl₂ once a week; (Group 2, 30 patients) the same PRP protocol combined with PDE5i; (Group 3, 15 patients): PRP inactivated once a week for three weeks. All groups showed a significant improvement in erectile function compared with baseline, and none of the adverse events were reported.³³ Furthermore, the authors concluded that PRP contains the necessary concentration of growth factors for a therapeutic effect. Nevertheless, in these studies, there was no placebo arm and no long-term evaluation was carried out". [25]

Matz et al. retrospectively examined "the safety and feasibility of platelet-rich fibrin matrix (PRFM) in four patients with erectile dysfunction, eleven with Peyronie's disease and one patient with both conditions. Among seven patients evaluated with IIEF-5, the latter increased on average by 4.14 points, while no major adverse events were reported in any patient".

Ruffo et al. evaluated "the effect of PRP combined with low-intensity shock wave therapy in two published trials. In the first study, 100 patients received shock wave therapy alone twice a week for 6 weeks (Group 1, 58 patients) or in combination with PRP injections once a week for 6 weeks (Group 2, 55 patients). In the other study, 112 patients received shock wave therapy once a week for 6 weeks only (Group 1, 53 patients) or in combination with PRP injections once every 2 weeks for 6 weeks (Group 2, 59 patients). In both trials, at 12"

and 24 weeks, the combined treatment significantly improved erectile function compared with baseline or shock wave monotherapy.

Ding et al. studied the effect of PRP on the regeneration and restoration of cavernous nerve function after injury. The PRP effect was studied 3 months later. PCI was measured to assess erectile function. EF in the PRP group was improved; PCI was significantly higher than that in the untreated group, but lower than that in the placebo group ($P < 0.05$). Cavernous nerve myelination in the PRP-treated group was significantly higher than in the untreated group, but

also lower than in the placebo group ($P < 0.05$). Study limitations included a small sample size and the administration of PRP at the site of cavernous nerve injury. In addition, the scientists used a non-standard method of electric field stimulation and a non-quantitative estimate of nerve regeneration was made.

Preclinical studies were also carried out in Taiwan by C Wu et al in 2012 and Y Wu et al in 2013. In the 2012 study, 60 rats in the experimental group received PRP therapy immediately after cavernous nerve injury. 4 weeks later, ICP was 1/3 higher in rats treated with PRP compared with animals that did not receive PRP therapy ($P < 0.05$). After treatment, the number of myelinated axons in the cavernous and dorsal nerves of the animals was significantly higher than in the untreated group. PRP administration significantly reduced the level of apoptotic markers (TGF- β 1, TUNEL, PI) and, consequently, apoptotic cells, including the cavernous body fibrosis marker TGF- β 1 ($P < 0.05$).

A reduction in fibrosis was also confirmed by histological study of penile tissue. Absence of type III collagen and prevalence of type I collagen was observed in specimens from the treated group. The authors believe that platelet granule growth factors acted as gas pedals of the nerve repair process due to their neuro-regenerative and neuroprotective properties, and inhibitors of the fibrosis process in the corpora cavernosa.

Conclusion

With the advent of IPDE5s, regenerative medicine therapy looks set to take on greater therapeutic importance. We consider our results to be promising and fruitful. Nevertheless, randomized studies with large patient samples are needed, as well as a focus on different treatment regimens. Precise coding of treatment doses and indications remains the cornerstone for standardization of this therapy.

Ethical Approval

This study was validated by the ethical committee of the Mohammed 6 University of Health Sciences, and was conducted at the regenerative medicine center of the CHEIKH KHALIFA University Hospital in Casablanca.

References

1. Andia I, Maffulli N. Platelet-rich plasma for managing pain

- and inflammation in osteoarthritis. *Nat Rev Rheumatol* 2013;9:721-30.
2. Jiritano F, Serraino GF, Rossi M, Dominijanni A, Brescia A, Renzulli A. Ventricular assist device driveline infection: treatment with platelet-rich plasma. *Ann Thorac Surg* 2013;96:e37-8.
 3. Marck RE, Middelkoop E, Breederveld RS. Considerations on the use of platelet-rich plasma, specifically for burn treatment. *J Burn Care Res* 2014;35:219-27.
 4. Schiavone G, Raskovic D, Greco J, Abeni D. Platelet-rich plasma for androgenetic alopecia: a pilot study. *Dermatol Surg* 2014;40:1010-9.
 5. Zhou B, Ren J, Ding C, Wu Y, Chen J, Wang G, et al. Protection of colonic anastomosis with platelet-rich plasma gel in the open abdomen. *Injury* 2014;45:864-8.
 6. Galliera E, Corsi MM, Banfi G. Platelet rich plasma therapy: inflammatory molecules involved in tissue healing. *J Biol Regul Homeost Agents* 2012;26(2 Suppl 1):35S-42S.
 7. Randelli P, Randelli F, Ragone V, Menon A, D'Ambrosi R, Cucchi D, et al. Regenerative medicine in rotator cuff injuries. *Biomed Res Int* 2014;2014:129515.
 8. Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. *Front Biosci* 2008;13:3532-48.
 9. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. *Physiol Rev* 2003;83:835-70.
 10. Xie X, Zhang C, Tuan RS. Biology of platelet-rich plasma and its clinical application in cartilage repair. *Arthritis Res Ther* 2014;16:204.
 11. Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. *Curr Rev Musculoskelet Med* 2008;1:165-74.
 12. Gigante A, Del Torto M, Manzotti S, Cianforlini M, Busilacchi A, Davidson PA, et al. Platelet rich fibrin matrix effects on skeletal muscle lesions: an experimental study. *J Biol Regul Homeost Agents* 2012;26:475-84.
 13. Kushida S, Kakudo N, Morimoto N, Hara T, Ogawa T, Mitsui T, et al. Platelet and growth factor concentrations in activated platelet-rich plasma: a comparison of seven commercial separation systems. *J Artif Organs* 2014;17:186-92.
 14. Wu CC, Wu YN, Ho HO, Chen KC, Sheu MT, Chiang HS. The

neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. *J Sex Med* 2012;9:2838-48.

16. Weiss RA. Autologous cell therapy: will it replace dermal fillers? *Facial PlastSurgClin North Am* 2013;21:299-304.

17. Derby CA, Araujo AB, Johannes CB, Feldman HA, McKinlay JB. Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study. *Int J Impot Res* 2000;12:197-204.

18. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Construction of a surrogate variable for impotence in the Massachusetts Male Aging Study. *J Clin Epidemiol* 1994;47:457-67.

19. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Vasiliadou C, Alexopoulos N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. *Eur Heart J* 2006;27:2640-8.

20. Li J, Shi Q, Pu C, Tang Y, Bai Y, Yuan H, et al. Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men. *Sci Rep* 2014;4:5801.

21. Greenfield JM, Levine LA. Peyronie's disease: etiology, epidemiology and medical treatment. *UrolClin North Am* 2005;32:469-78, vii.

22. Levine LA, Burnett AL. Standard operating procedures for Peyronie's disease. *J Sex Med* 2013;10:230-44.

23. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. *J Urol* 2013;190:199-207.

24. Davis NF, Kheradmand F, Creagh T. Injectable biomaterials for the treatment of stress urinary incontinence: their potential and pitfalls as urethral bulking agents. *Int Urogynecol J* 2013;24:913-9.

25. Epifanova MV, Gvasalia BR, Durashov MA, Artemenko SA. Platelet-rich plasma therapy for male sexualdysfunction: myth or reality?. *Sexualmedicinereviews*. 2020 Jan;8(1):106-13.

UNDER PEER REVIEW